REPLIGEN CORP Available-for-sale Securities, Amortized Cost Basis
REPLIGEN CORP (RGEN) had Available-for-sale Securities, Amortized Cost Basis of $19.55 million as of 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2017-02-23
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $19.55M.
- 2016-03-31: Available-for-sale Securities, Amortized Cost Basis $17.70M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $19.33M.
- 2015-09-30: Available-for-sale Securities, Amortized Cost Basis $22.43M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2016-12-31 | $19.55M 10-K · filed 2017-02-23 | |
| 2016-03-31 | $17.70M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $19.33M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $22.43M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $24.38M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $25.07M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $26.64M 10-K · filed 2016-02-25 | $26.64M 10-K · filed 2015-03-17 |
| 2014-09-30 | $28.17M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $28.16M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $32.46M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $34.02M 10-K · filed 2015-03-17 | |
| 2013-09-30 | $24.85M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $25.45M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $25.47M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $20.75M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $24.33M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $23.34M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $24.85M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |